Qulipta Shortage Update for 2026

If you rely on Qulipta (Atogepant) to prevent migraines, you may have heard concerns about shortages or had trouble filling your prescription. In this update, we'll cover the current state of Qulipta availability, why it can be hard to find, and what you can do about it in 2026.

Is Qulipta Still in Shortage?

As of early 2026, Qulipta is not listed on the FDA's official drug shortage database. This means there isn't a widespread manufacturing or supply issue affecting Qulipta at the national level.

However, that doesn't mean every pharmacy has it in stock. Many patients still report difficulty finding Qulipta at their local pharmacies. The issue isn't a traditional "shortage" — it's more of an availability gap caused by how specialty medications are distributed and stocked.

Why Is Qulipta Hard to Find?

Several factors contribute to Qulipta availability issues:

Limited Pharmacy Stocking

Qulipta is a brand-name specialty drug with a list price of $1,204.57 per 30-day supply (as of January 2026). Many retail pharmacies don't keep expensive specialty drugs on the shelf unless they have regular patients filling that prescription. If no one at your local pharmacy regularly fills Qulipta, they probably don't stock it.

No Generic Available

There is still no generic version of Atogepant on the market. While patent challenges became eligible in September 2025, no generic manufacturer has received FDA approval. This means only AbbVie's brand-name product is available, limiting supply channels.

Insurance and Prior Authorization Barriers

Most insurance plans require prior authorization for Qulipta, and some require step therapy (trying cheaper medications first). These administrative hurdles can delay prescriptions by days or weeks, making it seem like Qulipta is harder to access than it actually is.

Growing Demand

More doctors are prescribing CGRP-based treatments for migraine, and patient awareness has grown significantly. As demand increases, some pharmacies haven't adjusted their ordering patterns to keep up.

For a deeper dive into these issues, read: Why Is Qulipta So Hard to Find?

How Much Does Qulipta Cost in 2026?

Here's a breakdown of Qulipta pricing in 2026:

• Wholesale Acquisition Cost (list price): $1,204.57 per 30-day supply
• Retail cash price: $1,185 to $1,600 depending on the pharmacy and dose
• With GoodRx Gold: As low as $1,109 per month
• With SingleCare coupon: Around $1,018 for 30 tablets of 60 mg
• With AbbVie savings card: As little as $0 per month for eligible commercially insured patients
• Medicare Low Income Subsidy: Approximately $11 to $13 per month

For a complete guide to reducing your costs, see: How to Save Money on Qulipta in 2026.

New Options and Developments

The migraine prevention landscape continues to evolve in 2026:

• Expanded approval: Qulipta is now approved for both episodic and chronic migraine prevention, giving doctors more flexibility in prescribing.
• CGRP class growth: The overall CGRP class now includes multiple oral and injectable options, giving patients and providers more choices if one medication isn't available.
• Potential generic competition: With patent challenges eligible since September 2025, generic Atogepant could emerge in the coming years, which would increase availability and lower costs.

How to Find Qulipta in Stock

If your pharmacy doesn't have Qulipta, here's what to do:

1. Search on Medfinder — Check real-time pharmacy availability for Qulipta near you.
2. Try specialty pharmacies — These pharmacies focus on specialty drugs and are more likely to stock Qulipta.
3. Use mail-order pharmacy — Many insurance plans offer specialty mail-order delivery. Ask your insurer which pharmacy to use.
4. Ask your pharmacy to order it — Most pharmacies can get Qulipta within 1-2 business days if your insurance is approved.
5. Call AbbVie support — 1-855-QULIPTA (1-855-785-4782) for help locating Qulipta or accessing savings programs.

Read the full guide: How to Find Qulipta in Stock Near You.

Final Thoughts

Qulipta is not in a formal shortage in 2026, but finding it at your local pharmacy can still be a challenge. The main barriers are limited pharmacy stocking, insurance requirements, and the fact that there's no generic alternative yet.

The good news: there are tools and resources to help. Use Medfinder to locate pharmacies with stock, take advantage of AbbVie's savings programs, and work with your doctor to ensure your prior authorization is in place. If Qulipta remains out of reach, discuss alternative migraine preventives with your provider.